Cipla and Dr Reddy's also increased their share month on month. During the ... formoteral+budesonide and levocetirizine+montelukast drove growth in respiratory therapies,'' an analyst from ...

Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and further to 7.19% as of March 2025, according to the latest shareholding ...

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture and commercialise a biosimilar candidate to Keytruda (pembrolizumab ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda ...

CHENNAI: Shares of Dr Reddy’s Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a global licensing agreement with Alvotech, an Iceland-based ...

The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.

Dr Reddy's CFO Narasimham recently told to Moneycontrol he is confident of 'sustained double-digit sales growth' in FY26, with EBITDA and Return on Capital Employed (ROCE) at 25% or above. Some ...

Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.

Pharmaceutical major Dr Reddy’s Laboratories Limited (DRL) is facing a potential tax demand of over ₹2,395 crore from the Income Tax Authority. The demand, stems from the assessment year 2020 ...